目的 分析21-羟化酶缺乏症CYP21A2基因不同突变程度的初始治疗效果的差异性,为临床诊治及预后提供依据。 方法 回顾性分析2010年1月—2023年7月期间在青岛市新生儿疾病筛查中心筛查并基因确诊的34例患者的临床资料,联合应用多重链接依赖探针扩增技术及Sanger测序对致病基因CYP21A2进行检测,根据CYP21A2基因突变的残留酶活性,分为5个不同的基因型组:Null组(酶活性=0)、A组(酶活性<1%)、B组(酶活性2%~11%)、C组(酶活性约20%~50%)、D组(酶活性未知),探讨基因不同突变程度之间诊治指标的差异性。 结果 1)除外大片段缺失,34例患者中基因突变发生在内含子2区(29.82%)、第4外显子(28.07%)、第10外显子(12.28%)的比例较高,且第10外显子发生的突变种类较其他地区多。2)除外D组3例患儿(酶活性未知),本研究31例患儿的基因型-表型阳性预测值为90.32%。3)Null组、A组患儿均在1月内开始治疗,Null组、A组、B组、C组开始治疗的时间(H=11.568)、孕酮(H=13.864)、睾酮(H=13.249)、钠离子(H=17.370)、钾离子(H=19.613)、17-羟孕酮浓度(H=10.720)差异均有统计学意义(P<0.05);4个基因组间17-羟孕酮恢复正常时间、初始氢化可的松用量差异无统计学意义(P>0.05)。 结论 青岛地区34例患者的基因突变易发生在内含子2区、第4外显子、第10外显子,且第10外显子发生的突变种类较多。基因型-表型具有良好相关性,随酶活性降低而降低。基因突变程度对开始治疗的时间、17-羟孕酮、雄激素、电解质有显著影响,对17-羟孕酮恢复正常的时间、初始醋酸氢化可的松药量无显著影响。
Abstract
Objective To analyze the difference on initial therapeutic responses in patients with congenital adrenal hyperplasia (CAH) due to CYP21A2 gene mutations, stratified by residual enzymatic activity, in order to provide basis for clinical diagnosis, management, and prognosis prediction. Methods A retrospective analysis was conducted on the clinical data of 34 patients who were screened and genetically confirmed at the Qingdao Neonatal Disease Screening Center between January 2010 and July 2023. Multiplex Ligation-dependent Probe Amplification (MLPA) combined with Sanger sequencing was employed to detect pathogenic CYP21A2 mutations. Patients were grouped according to the residual enzymatic activity of mutated CYP21A2 into five genotypic categories: Null (activity=0), Group A (<1%), Group B (2% - 11%), Group C (20% - 50%), and Group D (activity unknown). Differences in diagnostic and treatment indicators among these mutation severity groups were analyzed. Results 1) In addition to the large fragments, mutations were more frequently detected in intron region 2(29.82%), exon 4(28.87%), and exon 10(12.28%), with exon 10 exhibiting the greatest variety of mutations than other areas. 2) Excluding 3 cases in Group D with unknown enzymatic activity, the positive predictive value of genotype-phenotype correlation for the remaining 31 patients was 90.32%.3) All children in the Null group and group A in Qingdao area started treatment within 1 month. Statistically significant differences were observed among Null, A, B, and C groups for the initiation time of treatment (H=11.568), progesterone (H=13.864), testosterone (H=13.249), sodium (H=17.370), potassium levels (H=19.613), and 17-hydroxyprogesterone concentrations (H=10.720) (P<0.05). However, no significant differences were noted in the time to normalization of 17-OHP levels or the initial dose of hydrocortisone among the four genotypic groups (P>0.05). Conclusions The gene mutations of 34 patients in Qingdao are prone to intron 2, exon 4 and exon 10, and there are many kinds of mutations in exon 10. There is a strong correlation between genotype and phenotype, which decreased with the decrease of enzyme activity. Mutation severity significantly influences the timing of treatment initiation and levels of 17-OHP, and rogens, and electrolytes, while having no significant effect on the time to 17-OHP normalization or the initial dosage of hydrocortisone required.
关键词
21-羟化酶缺乏症 /
CYP21A2基因突变 /
基因型-表型 /
新生儿疾病筛查
Key words
21-hydroxylase deficiency /
CYP21A2 gene mutation /
genotype-phenotype /
neonatal disease screening
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2018, 103(11): 4043-4088.
[2] 中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组,中国医师协会青春期医学专业委员会临床遗传学组,中华医学会儿科学分会内分泌遗传代谢学组.先天性肾上腺皮质增生症新生儿筛查共识[J].中华儿科杂志,2016,54(6): 404-409.
The Subspecialty Group of Newborn Screening, Society of Birth Defects Prevention and Control, Chinese Preventive Medicine Association, The Subspecialty Group of Clinical Genetics, Society of Adolescent Medicine, Chinese Medical Doctor Association, The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, The Society of Pediatrics, Chinese Medical Association. Consensus statement on neonatal screening for congenital adrenal hyperplasia[J]. Chin J Pediatr, 2016, 54(6): 404-409. (in Chinese)
[3] Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management[J]. Endocr Rev, 2022, 43(1): 91-159.
[4] 中华医学会儿科学分会内分泌遗传代谢病学组.先天性肾上腺皮质增生症21-羟化酶缺陷诊治共识[J].中华儿科杂志,2016,54(8):569-576.
The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association.Consensus statement on diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency[J]. Chin J Pediatr, 2016, 54(8): 569-576.(in Chinese)
[5] 中华预防医学会出生缺陷预防与控制专业委员会新生儿遗传代谢病筛查学组,国家卫生健康委员会临床检验中心新生儿遗传代谢病筛查室间质评专业委员会. 新生儿遗传代谢病筛查实验室检测技术规范专家共识[J].中华新生儿科杂志(中英文),2023,38(8):449-454.
Screening Group of Neonatal Genetic Metabolic Disease, Special Committee of Birth Defects Prevention and Control, Chinese Preventive Medical Association, Newborn Genetic Metabolic Disease Screening Laboratory Quality Evaluation Professional Committee from Clinical Laboratory Center of National Health Commission. Consensus on laboratory testing technical guidelines of neonatal genetic metabolic disease screening[J]. Chin J Neonatol, 2023, 38(8): 449-454.(in Chinese)
[6] 中华医学会儿科分会罕见病学组, 中国医师协会医学遗传医师分会, 中国妇幼保健协会出生缺陷防治与分子遗传分会,等.21羟化酶缺陷导致的先天性肾上腺皮质增生症的实验室诊断共识[J].中华医学遗传学杂志,2023,40(7):769-780.
Rare Diseases Group, Pediatric Branch of Chinese Medical Association, Medical Geneticists Branch of Chinese Medical Doctor Association, Birth Defect Prevention and Molecular Genetics Branch of China Maternal and Child Health Care Association,et al. Consensus on the laboratory diagnosis of congenital adrenal hyperplasia due to 21 hydroxylase deficiency[J]. Chin J Med Genet, 2023, 40(7): 769-780.(in Chinese)
[7] Concolino P, Costella A. Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency: A comprehensive focus on 233 pathogenic variants of CYP21A2 gene[J]. Mol Diagn Ther, 2018, 22(3): 261-280.
[8] 江载芳,申昆玲,沈颖.诸福棠实用儿科学[M]. 8版.北京:人民卫生出版社, 2015: 2153.
Jiang ZF,Shen KL, Shen Y, Zhu Futang practice pediatrics[M]. 8th ed. Beijing: People's Medical Publishing House, 2015: 2153.(in Chinese)
[9] Dolzan V, Solyom J, Fekete G, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia[J]. Eur J Endocrinol, 2005, 153(1): 99-106.
[10] 陶慧慧,陈曦,谭新睿,等.湖南地区21-羟化酶表型与基因型研究[J]. 中华实用儿科临床杂志,2020,35(9):686-690.
Tao HH, Chen X, Tan XR, etal.Analysis of clinical phenotype and genotype in patients with 21-hydroxylase deficiency in Hunan[J]. Chin J Appl Clin Pediatr,2020,35(9):686-690.(in Chinese)
[11] Haider S, Islam B, D'atri V, et al. Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia[J]. Proc Natl Acad Sci U S A, 2013, 110(7): 2605-2610.
[12] Wang C, Pallan PS, Zhang W, et al. Functional analysis of human cytochrome P45021A2 variants involved in congenital adrenal hyperplasia[J]. J Biol Chem, 2017, 292(26): 10767-1078.
[13] Li Z, Huang L, Du C, et al. Analysis of the screening results for congenital adrenal hyperplasia involving 7.85 million newborns in China: A systematic review and Meta-analysis[J]. Front Endocrinol (Lausanne), 2021(12):624507.
[14] Navarro-zambrana AN, Sheets LR. Ethnic and national differences in congenital adrenal hyperplasia incidence: A systematic review and Meta-analysis[J]. Horm Res Paediatr, 2022, 96(3): 249-258.
[15] 舒剑波,张新杰,徐晓薇,等.21-羟化酶缺乏症CYP21A2基因突变及表型分析[J]. 中华内分泌代谢杂志, 2019, 35(1): 21-25.
Shu JB, Zhang XJ, Xu XW, et al. Analysis of CYP21A2 gene mutation and phenotype in patients with 21-hydroxylase deficiency[J]. Chin J Endocrinol Metab, 2019, 35(1): 21-25.(in Chinese)
[16] 廖相云,张雅芬,顾学范. 21-羟化酶缺乏症患者CYP21基因点突变研究[J]. 中华儿科杂志, 2003, 41(9): 670-674.
Liao XY, Zhang YF,Gu XF. CYP21 gene point mutations study in 21-hydroxylase deficiency patients[J]. Chin J Pediatr, 2003, 41(9): 670-674.(in Chinese)
[17] 兰天,姚辉.经典型21-羟化酶缺乏症患儿基因型预测临床分型的研究[J].医学研究生学报,2020,33(10):1056-1060.
Lan T, Yao H. Clinical phenotype of genotype prediction in children with 21-hydroxylasedeficiency[J]. Journal of Medical Postgraduates, 2020, 33(10): 1056-1060.(in Chinese)
[18] New MI, Abraham M, Gonzalez B, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency[J]. Proc Natl Acad Sci U S A, 2013, 110(7): 2611-2616.
[19] Zhao Z, Gao Y, Lu L, et al. The underlying cause of the simple virilizing phenotype in patients with 21-hydroxylase deficiency harboring P31L variant[J]. Front Endocrinol (Lausanne), 2022(13):1015773.
[20] Wedell A, Luthman H. Steroid 21-hydroxylase (P450c21): A new allele and spread of mutations through the pseudogene[J]. Hum Genet, 1993, 91(3): 236-240.
[21] Dolzan V, Sólyom J, Fekete G, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia[J]. Eur J Endocrinol, 2005, 153(1): 99-106.
[22] Fox DA, Ronsley R, Khowaja AR, et al. Clinical impact and cost efficacy of newborn screening for congenital adrenal hyperplasia[J]. J Pediatr, 2020(220):101-108.e2.
基金
青岛市科技惠民示范引导专项任务(20-3-4-55-nsh)
PDF(809 KB)
